| 词条 | Luspatercept |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = | image = | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = Subcutaneous injection | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1373715-00-4 | UNII = AQK7UBA1LS | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = | DrugBank = | ChemSpiderID = none | C=3350 | H=5070 | N=906 | O=1044 | S=38 }}Luspatercept (ACE-536)[1] is an experimental drug in clinical trials for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It is being developed by Acceleron Pharma in collaboration with Celgene.[2] The FDA awarded orphan drug status in 2013 and fast track designation in 2015 for both indications.[3][4] Clinical developmentPhase III trials are evaluating the efficacy of luspatercept for the treatment of anemia in the hematological disorders beta thalassemia[5] and myelodysplastic syndromes.[6][4] StructureLuspatercept is a recombinant fusion protein derived from human activin receptor type IIb (ActRIIb) linked to a protein derived from immunoglobulin G.[7] References1. ^{{cite news|title=Luspatercept|url=http://adisinsight.springer.com/drugs/800029519|accessdate=15 February 2017|work=AdisInsight|language=en}} {{blood-drug-stub}}{{antineoplastic-drug-stub}}2. ^{{cite web|author=josh@comocreative.com |url=http://www.acceleronpharma.com/products/luspatercept/ |title=Luspatercept: Our Lead Product Candidate |publisher=Acceleronpharma.com |date= |accessdate=2017-05-22}} 3. ^{{cite web|url=http://www.businesswire.com/news/home/20150518005252/en/FDA-Fast-Track-Designation-Granted-Luspatercept-Treatment |title=FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia |publisher=Business Wire |date=2015-05-18 |accessdate=2017-05-22}} 4. ^1 {{cite web|title=Luspatercept|url=http://adisinsight.springer.com/drugs/800029519|website=AdisInsight|accessdate=1 February 2017}} 5. ^{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT02604433 |title=An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia - Full Text View |publisher=ClinicalTrials.gov |date= |accessdate=2017-05-22}} 6. ^{{cite web|url=https://clinicaltrials.gov/ct2/show/NCT02631070?term=NCT02631070 |title=A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes - Full Text View |publisher=ClinicalTrials.gov |date= |accessdate=2017-05-22}} 7. ^{{cite web | url = https://ncit.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI%20Thesaurus&code=C104012 | title = Luspatercept | work = NCI Thesaurus | publisher = National Cancer Institute}} 2 : Experimental drugs|Recombinant proteins |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。